{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:56Z","timestamp":1790880716051,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09736002"],"award-info":[{"award-number":["2018ZX09736002"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.intimp.2022.109248","type":"journal-article","created":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T05:18:19Z","timestamp":1663478299000},"page":"109248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis"],"prefix":"10.1016","volume":"112","author":[{"given":"Chen","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehong","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2022.109248_b0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1468-3083.2001.00192.x","article-title":"The prevalence of psoriasis in the world","volume":"15","author":"Raychaudhuri","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9583","key":"10.1016\/j.intimp.2022.109248_b0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2022.109248_b0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109248_b0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol"},{"issue":"11","key":"10.1016\/j.intimp.2022.109248_b0025","doi-asserted-by":"crossref","first-page":"e79253","DOI":"10.1371\/journal.pone.0079253","article-title":"Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation","volume":"8","author":"Swindell","year":"2013","journal-title":"PLoS"},{"key":"10.1016\/j.intimp.2022.109248_b0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.biochi.2020.09.023","article-title":"Inhibition of interleukin-2-inducible T-cell kinase causes reduction in imiquimod-induced psoriasiform inflammation through reduction of Th17 cells and enhancement of Treg cells in mice","volume":"179","author":"Nadeem","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.intimp.2022.109248_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106215","article-title":"Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23\/IL-17A in innate immune cells","volume":"80","author":"Nadeem","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.109248_b0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.phrs.2015.06.001","article-title":"Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC\/IL-17A pathway modulation","volume":"99","author":"Nadeem","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2022.109248_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104531","article-title":"Lck signaling inhibition causes improvement in clinical features of psoriatic inflammation through reduction in inflammatory cytokines in CD4+ T cells in imiquimod mouse model","volume":"376","author":"Al-Harbi","year":"2022","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2022.109248_b0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.02.014","article-title":"GPR43 activation enhances psoriasis-like inflammation through epidermal upregulation of IL-6 and dual oxidase 2 signaling in a murine model","volume":"33","author":"Nadeem","year":"2017","journal-title":"Cell. Signal."},{"key":"10.1016\/j.intimp.2022.109248_b0055","unstructured":"US Food and Drug Administration (FDA). Humira\u00ae (adalimumab) prescribing information. 2021. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125057s417lbl.pdf. (accessed on 3 May 2022)."},{"key":"10.1016\/j.intimp.2022.109248_b0060","unstructured":"European Medicines Agency (EMA). Humira\u00ae (adalimumab) summary of product characteristics. 2021. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf. (accessed on 3 May 2022)."},{"issue":"1","key":"10.1016\/j.intimp.2022.109248_b0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14712598.2020.1812576","article-title":"Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars","volume":"21","author":"Prignano","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2022.109248_b0070","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2040622318772705","article-title":"Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience","volume":"9","author":"Sator","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2022.109248_b0075","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.2310\/7750.2009.00022","article-title":"Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies","volume":"13","author":"Papp","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.intimp.2022.109248_b0080","article-title":"Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects","volume":"106","author":"Liu","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.109248_b0085","doi-asserted-by":"crossref","unstructured":"B. Strober, P. Foley, S. Philipp, N. Zhang, P. Kaur, Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results, J Am Acad Dermatol 74 (2016) (Suppl. 1): AB249.","DOI":"10.1016\/j.jaad.2016.02.972"},{"key":"10.1016\/j.intimp.2022.109248_b0090","unstructured":"U.S. Department of Health and Human Services. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. November 18, 2016."},{"key":"10.1016\/j.intimp.2022.109248_b0095","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. Available online: https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf. 2014 (accessed on 14 November 2016)."},{"key":"10.1016\/j.intimp.2022.109248_b0100","doi-asserted-by":"crossref","unstructured":"L. Kircik, N. Zhang, P. Kaur, Statistical considerations for demonstrating similarity and interpretation of clinical results in trials evaluating biosimilars, J Am Acad Dermatol 74 (2016) (Suppl.1):AB276.","DOI":"10.1016\/j.jaad.2016.02.1063"},{"issue":"6","key":"10.1016\/j.intimp.2022.109248_b0105","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","article-title":"Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study","volume":"76","author":"Papp","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109248_b0110","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/bjd.15857","article-title":"Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109248_b0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109248_b0120","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjd.18220","article-title":"AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"182","author":"Hercogov\u00e1","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"10086","key":"10.1016\/j.intimp.2022.109248_b0125","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.intimp.2022.109248_b0130","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.40444","article-title":"Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week Phase III randomized study results","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.intimp.2022.109248_b0135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2022.109248_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2015.06.038","article-title":"Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis","volume":"73","author":"Menter","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109248_b0145","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.109248_b0150","first-page":"30","article-title":"Biologic safety in psoriasis: review of long-term safety data","volume":"8","author":"Mansouri","year":"2015","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:46:51Z","timestamp":1761587211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922007329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"alternative-id":["S1567576922007329"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109248","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109248"}}